| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA434: Elotuzumab for previously treated multiple myeloma (terminated appraisal) |
|
Medicine details |
|
| Medicine name | elotuzumab (Empliciti®) |
| Formulation | powder for concentrate for solution for infusion |
| Reference number | 1155 |
| Indication | In combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 04/02/2016 |
| NICE guidance | TA434: Elotuzumab for previously treated multiple myeloma (terminated appraisal) |